Literature DB >> 27858559

Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.

Gyulnara G Kasumova1, Rebecca A Miksad1, Jennifer F Tseng1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27858559      PMCID： PMC5063190          DOI： 10.1200/JOP.2016.016923

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  9 in total

Review 1.  FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.

Authors:  Mustafa Suker; Berend R Beumer; Eran Sadot; Lysiane Marthey; Jason E Faris; Eric A Mellon; Bassel F El-Rayes; Andrea Wang-Gillam; Jill Lacy; Peter J Hosein; Sing Yu Moorcraft; Thierry Conroy; Florian Hohla; Peter Allen; Julien Taieb; Theodore S Hong; Ravi Shridhar; Ian Chau; Casper H van Eijck; Bas Groot Koerkamp
Journal:  Lancet Oncol       Date:  2016-05-06       Impact factor: 41.316

2.  Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz
Journal:  J Clin Oncol       Date:  2016-05-31       Impact factor: 44.544

3.  Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis.

Authors:  S W L de Geus; D B Evans; L A Bliss; M F Eskander; J K Smith; R A Wolff; R A Miksad; M C Weinstein; J F Tseng
Journal:  Eur J Surg Oncol       Date:  2016-08-09       Impact factor: 4.424

Review 4.  Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.

Authors:  Susan Tsai; Kathleen K Christians; Paul S Ritch; Ben George; Abdul H Khan; Beth Erickson; Douglas B Evans
Journal:  J Oncol Pract       Date:  2016-10       Impact factor: 3.840

5.  Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators.

Authors:  Matthew H G Katz; Jason B Fleming; Priya Bhosale; Gauri Varadhachary; Jeffrey E Lee; Robert Wolff; Huamin Wang; James Abbruzzese; Peter W T Pisters; Jean-Nicolas Vauthey; Chusilp Charnsangavej; Eric Tamm; Christopher H Crane; Aparna Balachandran
Journal:  Cancer       Date:  2012-05-17       Impact factor: 6.860

Review 6.  Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.

Authors:  V Heinemann; M Haas; S Boeck
Journal:  Ann Oncol       Date:  2013-07-12       Impact factor: 32.976

Review 7.  Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.

Authors:  Gauri R Varadhachary; Eric P Tamm; James L Abbruzzese; Henry Q Xiong; Christopher H Crane; Huamin Wang; Jeffrey E Lee; Peter W T Pisters; Douglas B Evans; Robert A Wolff
Journal:  Ann Surg Oncol       Date:  2006-07-24       Impact factor: 5.344

8.  Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.

Authors:  Pascal Hammel; Florence Huguet; Jean-Luc van Laethem; David Goldstein; Bengt Glimelius; Pascal Artru; Ivan Borbath; Olivier Bouché; Jenny Shannon; Thierry André; Laurent Mineur; Benoist Chibaudel; Franck Bonnetain; Christophe Louvet
Journal:  JAMA       Date:  2016-05-03       Impact factor: 56.272

9.  EMT and dissemination precede pancreatic tumor formation.

Authors:  Andrew D Rhim; Emily T Mirek; Nicole M Aiello; Anirban Maitra; Jennifer M Bailey; Florencia McAllister; Maximilian Reichert; Gregory L Beatty; Anil K Rustgi; Robert H Vonderheide; Steven D Leach; Ben Z Stanger
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.